Toxic neuropathies: a practical approach

Smyth, Duncan; Kramarz, Caroline; Carr, Aisling; Rossor, Alexander M.; Lunn, Michael P.

doi:10.1136/pn-2022-003444

Cited by 7 publications

(3 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Considering this information, it can be postulated that nitrofurantoin might possess convulsive effect (23). However, the mechanism upon which nitrofurantoin causes neurological impairment differs from toxins like Ciguatoxin, which might be associated with their different ligand binding sites in the sodium channels (24). Therefore, this hypothesis is refused.…”

Section: Discussionmentioning

confidence: 99%

The Effect of Nitrofurantoin on Tonic Seizures Induced by MES in Male Mice

Jalalian,

Shafaroodi,

Fereydani

2024

ACTA

View full text Add to dashboard Cite

Antibiotics are medicines that fight against bacterial infections and are usually considered safe drugs. However, they can simultaneously cause several adverse reactions. Nitrofurantoin, which is mainly administered for treatment and prevention of urinary tract infections, causes seizure reportedly. Therefore, further research is required to be conducted to simulate the case report situations and examine whether nitrofurantoin is the main factor leading to seizures. To do this, NMRI male mice (20-30 gr) were chosen and classified into different groups in both acute and chronic phases. Each phase contained mice treated with nitrofurantoin, phenytoin and the combination of both drugs as well as untreated control group. An Electroshock device was used to induce seizure in mice and then the effect of nitrofurantoin and phenytoin was examined in acute and chronic phases. Seizure induction in mice was examined 30 minutes and one week after injection in acute and chronic phases, respectively. Results indicated that THE (Tonic Hind-limb Extension) duration was different among the studied groups. Nitrofurantoin-injected mice were revealed to have a higher THE duration in comparison with control group, while phenytoin-injected group showed a lower THE duration. Furthermore, administration of nitrofurantoin and phenytoin combination reduced THE duration in both acute and chronic phases. Our conclusion is that nitrofurantoin can possess convulsive effects and cause seizure as a side effect.

show abstract

Section: Discussionmentioning

confidence: 99%

The Effect of Nitrofurantoin on Tonic Seizures Induced by MES in Male Mice

Jalalian,

Shafaroodi,

Fereydani

2024

ACTA

View full text Add to dashboard Cite

show abstract

“…Also, prior treatment lines, including cytotoxic drugs that may cause neurotoxicity, such as oxaliplatin, should be taken into account when reporting neuropsychiatric ADRs in pretreated CRC patients (40). Furthermore, the role of prior radiation therapy and the administration of immune checkpoint inhibitors (ICIs) could impair neuronal repair and exacerbate nerve toxicity with REG (41,42). Moreover, hyperaesthesia, thermohyperaesthesia, hypoaesthesia, and burning sensation, can be considered as consequential symptoms of neuropathy, as already known in the literature (18).…”

Section: Discussionmentioning

confidence: 99%

Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System

Barbieri,

Russo,

Sorbara

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

IntroductionNew oral tyrosine kinase inhibitors (TKIs) are approved for metastatic colorectal cancer (mCRC). The aim of this study was to assess the neuropsychiatric adverse drug reactions (ADRs) of these drugs reported in the FDA Adverse Event Reporting System (FAERS) database.MethodsAll reports with regorafenib (REG) and encorafenib (ENC) as the primary suspect, and reported in the FAERS between 2012 and 2022, were collected. A descriptive and disproportionality analyses were conducted.ResultsOut of 4,984 cases, 1,357 (30.2%) reported at least one neuropsychiatric ADR. New potential signals for REG included neuropathy peripheral (n = 265; reporting odds ratio, ROR = 19.48, 95% confidence interval, CI 95% = 17.52-22.47; information component, IC = 2.89, IC025-IC075 = 2.77-3.02), hyperesthesia (n = 18; ROR = 12.56, CI 95% = 7.90-19.96; IC = 2.25, IC025-IC075 = 1.79-2.72), taste disorder (n = 41; ROR = 9.91, CI 95% = 7.29-13.49; IC = 2.18, IC025-IC075 = 1.88-2.49), poor quality sleep (n = 18; ROR = 6.56, CI 95% = 4.13-10.42; IC = 1.74, IC025-IC075 = 1.27-2.20), altered state of consciousness (n = 15; ROR = 5.50, CI 95% = 3.31-9.14; IC = 1.57, IC025-IC075 = 1.06-2.07), depressed mood (n = 13; ROR = 1.85, CI 95% = 1.07-3.19; IC = 0.58, IC025-IC075 = 0.04-1.13) and insomnia (n = 63; ROR = 1.48, CI 95% = 1.15-1.89; IC = 0.38, IC025-IC075 = 0.13-0.63). For ENC comprised depressed mood (n = 4; ROR = 5.75, CI 95% = 2.15-15.39; IC = 1.74, IC025-IC075 = 0.76-2.73) and cognitive disorders (n = 3; ROR = 4.71, CI 95% = 1.51-14.66; IC = 1.54, IC025-IC075 = 0.41-2.68).DiscussionThis study identified new unknown potential neuropsychiatric ADRs. Further investigations are required to better define the neurotoxicity of TKIs in mCRC patients.

show abstract

“…По некоторым литературным данным исследуемое соединение обладает значительной токсичностью по отношению к теплокровным организмам. При изучении токсических свойств на лабораторных животных (крысы) LD 50 для анализируемого соединения -0,43 г/кг, для мышей LD 50 (в/в введение) -0,21 г/кг [2].…”

unclassified

Determination of Mexidol in tablets by the method of derivative spectrophotometry

Kvachakhiya,

Shormanov,

Maksina

2023

Humans and their Health

View full text Add to dashboard Cite

Mexidol (3-hydroxy-6-methyl-2-ethylpyridine succinate) is a drug that exhibits neuroprotective, antihypoxic, anti-ischemic, nootropic, anti-stress and geroprotective effects and can suppress or slow down oxidation reactions. Оbjective: to develop a selective and simple method for assessing the content of mexidol in tablets. Materials and methods. The objects of the study were mexidol (3-hydroxy-6-methyl-2-ethylpyridine succinate) and Mexidol tablets 0.125 g. Derivative spectrophotometry was used as an analysis method. Results. The ability of mexidol to intensively absorb electromagnetic radiation in the quartz ultraviolet region was revealed. This phenomenon is due to the fact that the analyte molecule contains a number of chromophore groups: a system of conjugated aromatic bonds of the pyridine ring, unpaired electrons at the nitrogen atom, and an enol hydroxyl conjugated with the aromatic system In the region of 292 nm, there is a linear dependence of the derivatives of the 2nd order of the specific absorption coefficient of mexidol on the amount of analyte in the photometric solution (range 2.5-50.0 μg/ml). A calibration graph has been constructed, and its equation has been calculated by the least-squares method. The correlation coefficient exceeds 0.999. The limits of detection and quantification are 1.25 and 2.5 µg/ml, respectively. The technique is characterized by the necessary reproducibility and correctness. The values of the standard deviation and relative standard deviation in the determination of the analyte using the proposed method (n=6; P=0.95) in the tablet mass are 1.16 and 0.012, respectively, in tablets of 0.125 g, 1.32 and 0.013, respectively. Conclusion. A simple and selective method has been developed for estimating the quantitative content of mexidol in 0.125 g tablets based on the calculation of second-order derivatives of spectra.

show abstract

Toxic neuropathies: a practical approach

Cited by 7 publications

References 59 publications

The Effect of Nitrofurantoin on Tonic Seizures Induced by MES in Male Mice

The Effect of Nitrofurantoin on Tonic Seizures Induced by MES in Male Mice

Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System

Determination of Mexidol in tablets by the method of derivative spectrophotometry

Contact Info

Product

Resources

About